Roivant Announces Positive Results From PHocus Study Of Mosliciguat In Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) And Unveils Ongoing Phase 3 PHrontier Study
ROIV•PHocus study results and Phase 3 update
Sept. 8 (Reuters) - Roivant Sciences Ltd ROIV.O:
- Roivant announces positive results from PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and unveils ongoing Phase 3 PHrontier study
- PHocus met its primary endpoint
- Mosliciguat shows lower cough incidence than placebo in PHocus study
- The study also met its secondary endpoints at week 16
- Mosliciguat was observed to be well tolerated with a favorable safety profile
